Stanley Black & Decker Reports Record 1Q 2021 Results
News provided by
Share this article
Share this article
NEW BRITAIN, Conn., April 28, 2021 /PRNewswire/ Stanley Black & Decker (NYSE: SWK) today announced first quarter 2021 financial results.
1Q 21 Revenues Totaled $4.2 Billion, Up 34% Versus Prior Year Led By Tools & Storage With All Segments Contributing To 31% Organic Growth
1Q 21 Gross Margin Was 37.3%; Excluding Charges, 1Q 21 Gross Margin Was 37.4% Up 440 Basis Points Versus Prior Year
1Q 21 Operating Margin Was 16.9%; Excluding Charges 1Q 21 Operating Margin Was 17.6%, Up 760 Basis Points Versus Prior Year Driven By Volume, Price, Cost Control And Margin Resiliency
1Q 21 Diluted GAAP EPS Was $2.98; Excluding Charges, 1Q 21 Diluted EPS Was $3.13, Up 161% Versus Prior Year
Stanley Black & Decker, Inc to Redeem Its Series C Cumulative Perpetual Convertible Preferred Stock
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Stanley Black & Decker Reports Record 1Q 2021 Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SEATTLE, April 7, 2021 /PRNewswire/ AVM Biotechnology announced today that the first cohort has been fully enrolled in their clinical study (NCT04329728 The WWRD Study ). All three patients had failed multiple prior therapies, and one had failed two transplants. These patients are reportedly all doing very well, and one was quoted as saying, I feel great! Three major US Cancer Centers are actively enrolling study participants. AVM Biotechnology is excited to advance AVM0703 to the next dose level cohort of no-option lymphoma patients. The drug has been well tolerated, without safety issues, as expected. The study is an adaptive design/expansion cohort trial such that cohort enrollment of relapsed/refractory Non-Hodgkin s Lymphoma patients for the pivotal trial can immediately follow the dose-escalation phase.